

CLAIMS

- sub B1*
1. An antigenic fusionprotein, which carries multiple Gal α 1,3Gal epitopes.
- 5 2. An antigenic fusionprotein according to claim 1, which is produced by a recombinant cell line.
- sub B2*
3. An antigenic fusionprotein according to ~~any one of claims 1 and 2~~, which is capable of binding preformed antibodies as well as antibodies produced as a response to a tissue or an organ originating from the species in which the Gal α 1,3Gal epitope is expressed, said species preferably being a species different from the antibody producing species.
- 15 4. An antigenic fusionprotein according to ~~any one of the preceding claims~~, wherein the Gal α 1,3Gal epitopes have been made by an α 1,3 galactotransferase derived from a porcine species. *claim 1*
- sub B3*
5. An antigenic fusionprotein according to ~~any one of the preceding claims~~, which further comprises a part which mediates binding to selectins. *claim 7*
- 20 6. An antigenic fusionprotein according to claim 5, wherein the selectin is P-selectin.
- 25 7. An antigenic fusionprotein according to claim 5, wherein the part that mediates binding to selectin is a highly glycosylated protein, preferably a protein of mucin type.
- sub B4*
8. An antigenic fusionprotein according to claim 7, wherein the part that mediates binding to selectin is the P-selectin glycoprotein ligand-1 (PSGL-1) or an essential part thereof.
- 30 9. An antigenic fusionprotein according to ~~any one of the preceding claims~~, which further comprises a part which confers immunoglobulin properties. *claim 1*
- 35 10. An antigenic fusionprotein according to claim 9, wherein said part that confers immunoglobulin properties is an immunoglobulin or a part thereof, preferably IgG or a part thereof.
- sub B5*

11. An antigenic fusionprotein according to claim 10, wherein said part that confers immunoglobulin properties is the Fc part of an immunoglobulin, preferably IgG, or an essential part thereof.

12. An antigenic fusionprotein according to claim 11, wherein said part that confers immunoglobulin properties is IgG_{2b}, preferably the Fc part thereof.

13. An antigenic fusionprotein according to ~~any one of claims 9-12~~, wherein said part that confers immunoglobulin properties is of human origin.

10

14. An antigenic fusionprotein according to ~~any one of the claims 9-12~~, wherein said part that confers immunoglobulin properties is of non-human origin and preferably is derived from mouse.

15

15. A cDNA molecule comprising a cDNA sequence coding for a fusionprotein according to ~~any one of claims 1-14~~ or a derivative or variant thereof.

16. A vector which comprises a cDNA molecule according to claim 15 together with appropriate control and signal sequences.

20

17. A mammalian cell transfected with a vector according to claim 16.

18. A mammalian cell according to claim 17, which is a COS cell.

25

19. An absorber for use in the purification of blood plasma from antibodies raised against a foreign tissue or organ, which absorber comprises a fusion protein according to ~~any one of claims 1-14~~.

30

20. A method for preventing a hyperacute rejection reaction in a patient who is to receive a xenotransplant, which method comprises withdrawal of plasma from the patient, bringing said plasma in contact with a fusionprotein according to ~~any one of claims 1-14~~ to couple anti-pig antibodies thereto and thereafter reinfusing the plasma to the patient.

Adol
D1